Anti-PTHrP vaccine - Pepscan Therapeutics

Drug Profile

Anti-PTHrP vaccine - Pepscan Therapeutics

Latest Information Update: 23 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pepscan Systems
  • Developer Pepscan Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypercalcaemia

Most Recent Events

  • 23 May 2012 No development reported - Preclinical for Hypercalcaemia in Netherlands (Parenteral)
  • 24 Mar 2009 Preclinical development is ongoing in the Netherlands
  • 26 Nov 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top